Evidence map›Paper›PMID 42592425›Full record

ArticleActa pharmaceutica Sinica. B2026

A novel small molecule inhibitor targeting KHSRP methylation suppresses colon cancer progression.

Shuang Chen, Ningjing Zhang, Yuxiao Zhang, Jiebin Fang, Zhen Tang, Dashan Zhang, Xinyi Tang, Yalin Yu, Mengde Xia, Yan Yi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shuang ChenHainan Institute, Zhejiang University, Sanya 572025, China.
Ningjing ZhangInstitute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China.
Yuxiao ZhangInstitute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China.
Jiebin FangHainan Institute, Zhejiang University, Sanya 572025, China.
Zhen TangSchool of Life Sciences, Westlake University, Hangzhou 310000, China.
Dashan ZhangCenter of Synthetic Biology and Integrated Bioengineering, Westlake University, Hangzhou 310000, China.
Xinyi TangInstitute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China.
Yalin YuInstitute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China.
Mengde XiaHainan Institute, Zhejiang University, Sanya 572025, China.
Yan YiInstitute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China.
Wanjing DingInstitute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China.
Zhongjun MaHainan Institute, Zhejiang University, Sanya 572025, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA-binding proteins (RBPs) are emerging as crucial regulators in cancer, but the development of therapeutic strategies targeting RBPs remains limited. Here, through chemical proteomics approaches, we identify DIQ01 as a novel small-molecule inhibitor of KH-type splicing regulatory protein (KHSRP), an RBP that is aberrantly hyper-expressed in human tumors and plays an essential role in proliferation, metastasis, and tumor progression. DIQ01 specifically binds to the KH3 and KH4 domains (Phe358 as the key residue) of KHSRP, inhibiting its interaction with mRNAs. Furthermore, the binding of DIQ01 diminishes the PRMT5-mediated arginine methylation of KHSRP, a post-translational modification required for its oncogenic activity. Mechanistically, transcriptomic and proteomic profiling suggested that DIQ01 functionally inactivates KHSRP, triggering destabilization and downregulation of its target

Indexed as

ABPPArginine methylationColon cancerDNA damageKHSRPPLK1PRMT5Small molecule inhibitor

Identifiers

PMID42592425
PMCPMC13464083

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.